Bioresorbable everolimus-eluting vascular scaffold in patients with ST-segment elevation myocardial infarction: Optical coherence tomography evaluation and clinical outcomes

Kochman, Janusz; Tomaniak, Mariusz; Pietrasik, Arkadiusz; Kołtowski, Łukasz; Rdzanek, Adam; Huczek, Zenon; Mazurek, Tomasz; Jąkała, Jacek; Ząbek, Aldona; Legutko, Jacek; Kochman, Wacław; Filipiak‬, Krzysztof J.

doi:10.5603/cj.a2014.0090

Cited by 10 publications

(5 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This registry suggested that when accurate BRS implantation technique was used, an unrestricted BRS use would be safe and effective. 17) 18) 19) 20) 21) In addition, BRS was evaluated in the complex patients and lesions subset including diabetes, 22) ACS, 23) 24) 25) MI, 26) 27) 28) 29) 30) 31) 32) 33) small vessel, 34) and in-stent restenosis. 35) 36) 37) However, the interpretation of such studies should be careful considering the biased nature of registry studies.…”

Section: Current Evidencementioning

confidence: 99%

Bioresorbable Vascular Scaffold Korean Expert Panel Report

et al. 2017

View full text Add to dashboard Cite

Bioresorbable vascular scaffold (BRS) is an innovative device that provides structural support and drug release to prevent early recoil or restenosis, and then degrades into nontoxic compounds to avoid late complications related with metallic drug-eluting stents (DESs). BRS has several putative advantages. However, recent randomized trials and registry studies raised clinical concerns about the safety and efficacy of first generation BRS. In addition, the general guidance for the optimal practice with BRS has not been suggested due to limited long-term clinical data in Korea. To address the safety and efficacy of BRS, we reviewed the clinical evidence of BRS implantation, and suggested the appropriate criteria for patient and lesion selection, scaffold implantation technique, and management.

show abstract

Section: Current Evidencementioning

confidence: 99%

Bioresorbable Vascular Scaffold Korean Expert Panel Report

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Of note, in the multivariate analysis, BVS was not associated with the incidence of MACE (P>0.9). More recently, Kochman et al 42 performed an OCT assessment of acute procedural results of BVS implantation in 23 STEMI patients, also evaluating midterm clinical outcomes. Procedural and clinical success rates were 95.7%, whereas the device success rate was 100%.…”

Section: Evidence For Bvs Use In Patients With Acute Coronary Syndromesmentioning

confidence: 99%

Coronary Bioresorbable Vascular Scaffold Use in the Treatment of Coronary Artery Disease

Testa

Latib

Montone

et al. 2016

Circ: Cardiovascular Interventions

View full text Add to dashboard Cite

Bioresorbable vascular scaffolds (BVS) represent a promising novel approach for the treatment of coronary artery disease. BVS promise to address some of the well-known limitations of current drug-eluting stents, while providing a transient scaffolding of the vessel to prevent acute vessel closure/recoil. Drug elution by BVS prevents neointimal proliferation in a similar fashion to drug-eluting stents, and complete bioresorption is associated with late vessel lumen enlargement, plaque regression, and restoration of vasomotion. Based on the pathophysiological reasons and on the results derived from clinical studies, BVS are increasingly being used in clinical practice. The aim of this review is to provide an overview of the current evidence supporting the use of BVS in clinical practice. In particular, we will discuss the randomized controlled trials and registries evaluating the clinical outcome of these devices, with a special focus on their application in patients with acute coronary syndrome and in specific lesion subsets (bifurcations, chronic total occlusions, and in-stent restenosis).

show abstract

“…At the 30-day follow-up, the target lesion failure rate was 0% and no cases of cardiac death or ScT were observed. Kochman et al (23) performed an OCT assessment of acute procedural results of BVS implantation in 23 STEMI patients, demonstrating a high strut apposition rate (>95%) immediately after implantation. In a median follow-up period of 229 (range, 199-248) days, 1 MI, caused by sub-acute ScT, occurred in a patient who discontinued dual antiplatelet therapy (DAPT).…”

Section: Single-center Registriesmentioning

confidence: 99%

Are acute coronary syndromes an ideal scenario for bioresorbable vascular scaffold implantation?

Moscarella

Ielasi²,

Angelis

et al. 2017

J. Thorac. Dis.

View full text Add to dashboard Cite

Bioresorbable vascular scaffolds (BRS) represent the latest innovation in the field of interventional cardiology. BRS have recently been introduced in routine clinical practice and their use has progressively extended in everyday clinical practice. The BRS use appears theoretically attractive in patients presenting with acute coronary syndromes (ACS) as they are generally young with long life expectancy, thus possibly benefiting more of the so-called vascular reparative therapy. Furthermore, "culprit" lesions are usually softer and more easily expandable by current BRS compared to stable chronic lesions. However an increased risk of BRS thrombosis has been reported in clinical trials excluding ACS patients. Therefore, concerns have been raised on the safety of BRS implantation in the ACS setting in which the risk of thrombotic recurrences is definitely higher (compared to stable lesions) independently by the device implanted. Aim of this review is to provide an overview of the available data on the BRS performance in ACS patients.

show abstract

Bioresorbable everolimus-eluting vascular scaffold in patients with ST-segment elevation myocardial infarction: Optical coherence tomography evaluation and clinical outcomes

Abstract: Background: Bioresorbable vascular scaffold (BVS) implantation is a new, promising treatment method of coronary artery disease. Preliminary data in patients with (Cardiol J 2015; 22, 3: 315-322)

Cited by 10 publications

References 36 publications

Bioresorbable Vascular Scaffold Korean Expert Panel Report

Bioresorbable Vascular Scaffold Korean Expert Panel Report

Coronary Bioresorbable Vascular Scaffold Use in the Treatment of Coronary Artery Disease

Are acute coronary syndromes an ideal scenario for bioresorbable vascular scaffold implantation?

Contact Info

Product

Resources

About